TheraRadar
Data updated: May 26, 2026

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE (glimepiride)

Metabolic Approved 2016-04-01
1
Indication
--
Phase 3 Trials
10
Years on Market

Details

Status
Discontinued
First Approved
2016-04-01
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: GLIMEPIRIDE , ROSIGLITAZONE MALEATE

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE Approval History

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
5 FDA actions from 2016 to 2016
Apr 2016 ORIGINAL
Update

What ROSIGLITAZONE MALEATE AND GLIMEPIRIDE Treats

1 FDA approvals

Originally approved for its first indication in 2016 .

  • Other (1)
📋

Clinical Trial Registry

82 trials
Trial Sponsor ID Phase Status Title
NCT03118713 1941-MA-3122-KR Ph 4 terminated A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
NCT02956044 results posted THR-1442-C-453 Ph 1 completed Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
NCT02649465 CRB4180005 Ph 4 completed SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
NCT02769481 results posted THR-1442-C-480 Ph 3 completed Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
NCT03332771 SOTA-GLIM results posted EFC14838 2016-001801-17, U1111-1190-7596 Ph 3 completed Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
NCT02973477 results posted HUM00121107 Ph 4 completed Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
NCT02419612 results posted CV181-365 Ph 3 completed A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
NCT02694263 Can Do 0527 Ph 4 completed Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
NCT01243424 results posted 1218.74 2009-013157-15 Ph 3 completed CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
NCT02072096 IMPERIUM results posted 14842 F3Z-MC-IOQL, 2013-001473-24 Ph 4 terminated A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
NCT01644500 AWARD-CHN1 results posted 11991 H9X-JE-GBCG Ph 3 completed A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
NCT02564926 BEYOND results posted D1690L00067 Ph 4 completed Foxiga Korea Local Phase 4 Study
NCT02312063 DIET results posted KEP26-49 Ph 4 completed Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes
NCT02471404 results posted D1689C00014 Ph 4 completed Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
NCT02728453 EMPATROPHY CRC-KliPha-001 Ph 4 terminated SGLT2 Inhibition and Left Ventricular Mass
NCT02373865 results posted DIA-2-REDESIGN Ph 4 terminated Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
NCT02630706 results posted 8835-012 B1521045, MK-8835-012 Ph 3 completed A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
NCT02985242 M16-04EMPA-EYE 2016-000825-38 Ph 4 terminated Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
NCT02036515 results posted 8835-006 2013-003697-26, B1521015 Ph 3 completed Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
NCT02226003 results posted 8835-017 2014-001049-25, B1521047 Ph 3 completed Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
NCT01717313 results posted 3102-011 2012-003626-24 Ph 3 completed A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
NCT01755156 results posted 3102-024 2012-003670-11 Ph 3 completed A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
NCT01704261 results posted 3102-022 2012-002612-10 Ph 3 completed Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
NCT01863667 results posted 3102-027 2013-000301-23 Ph 3 terminated A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
NCT01682759 results posted 3102-016 MK-3102-016 Ph 3 completed A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
NCT01678820 results posted 0431D-266 Ph 3 terminated A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
NCT01709305 results posted 0431-313 Ph 4 completed A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
NCT01590771 results posted 0431-253 Ph 3 completed A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
NCT01177384 results posted 0431-130 2010_543, CTRI/2011/10/002072 Ph 3 completed Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
NCT02280486 SPECIFY ISSSAXA0014 Ph 4 completed Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin
NCT01958671 results posted 8835-003 2013-002519-90, B1521022 Ph 3 completed A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
NCT02484209 DiaFrail DF-07 Ph 3 withdrawn DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)
NCT02007278 GLOBE results posted CLAF237ACO01 Ph 4 completed Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
NCT01296412 results posted 0431-403 Ph 3 completed Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
NCT01189890 results posted 0431-251 Ph 3 completed Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
NCT00858013 results posted AJIRB-CRO-08-197 Ph 4 completed Study of the Durability of Glycemic Control With Nateglinide
NCT00614120 results posted NN2211-1796 Ph 3 completed Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00620282 results posted NN2211-1799 Ph 3 completed The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
NCT01123980 EasyMix results posted BIASP-3756 U1111-1114-4112, JapicCTI-101139 Ph 4 completed Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
NCT01517373 results posted B1621002 2011-005206-30 Ph 2 completed Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
NCT00968812 results posted CR016480 28431754DIA3009, 2009-009320-36 Ph 3 completed CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
NCT00839527 results posted 112757 Ph 3 completed A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
NCT00838903 results posted 112753 Ph 3 completed Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
NCT01262586 CLAF237A23151 2010-021236-34 Ph 3 completed Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
NCT00562250 MB102-016 Ph 1 completed Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
NCT00842556 MB102-037 Ph 1 completed Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
NCT01167881 results posted 1245.28 2009-016244-39 Ph 3 completed Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
NCT01425580 EU-nr 2010-022695-31 2010-022695-31 Ph 2 completed Liraglutide and Heart Failure in Type 2 Diabetes
NCT01829477 results posted TAK-875_309 2013-000007-17, U1111-1138-8680 Ph 3 terminated Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
NCT01481116 results posted TAK-875_304 2011-001731-24, U1111-1124-2296 Ph 3 terminated Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Showing 50 of 82 trials

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE FDA Label Details

Track ROSIGLITAZONE MALEATE AND GLIMEPIRIDE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.